CTRI/2018/08/015167已完成未知
A Randomised, Double-blind, Multicentre, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study to Compare the Efficacy and Safety of Clindamycin Phosphate 10 mg/g and Benzoyl Peroxide 50 mg/g Gel (Morningside Healthcare Ltd, UK) versus DUAC Once Daily 10 mg/g and 50 mg/g Gel (GlaxoSmithKline UK Limited) in Subjects with Acne Vulgaris.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 530
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy male or non-pregnant female aged more than or equal to 12 and less than or equal to 40 years with a clinical diagnosis of Acne vulgaris.
- •2. On the face, more than or equal to 25 non-inflammatory lesions (i.e., open and closed comedones) AND more than or equal to 20 inflammatory lesions (i.e., papules and pustules) AND less than or equal to 2 nodules.
- •3. Investigatorâ??s Global Assessment (IGA) of acne severity grade 2, 3 or 4.
- •4. Willing to refrain from use of all other topical acne medications or antibiotics during the 11 week treatment period.
- •5. If female of childbearing potential, willing to use an acceptable form of birth control during the study.
- •6. Willing to provide written informed consent or assent, as applicable.
排除标准
- •1. Presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis).
- •2. Subjects who have acne conglobata, acne fulminans, nodulocystic acne and secondary acne (e.g. chloracne and drug induced acne).
- •3. Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris. Well-trimmed moustaches are allowed.
- •4. History of hypersensitivity or allergy to clindamycin or lincomycin or benzoyl peroxide and/or any of the study medication ingredients.
- •5. Use within 6 months prior to baseline (Randomisation) of oral retinoids (e.g. Accutane) or therapeutic vitamin A supplements of greater than 10,000 units per day (multivitamins are allowed).
- •6. Use for less than 3 months prior to baseline (Randomisation) of estrogens or oral contraceptives; use of such therapy is allowed if it will remain constant throughout the study.
- •7. Use on the face within 1 month prior to baseline (Randomisation) of 1) cryodestruction or chemodestruction, 2) dermabrasion / microdermabrasion, 3) photodynamic therapy, 4) acne surgery, 5) intralesional steroids, 6) X-ray therapy, or 7) chemical or laser peel.
- •8. Use within 1 month prior to baseline (Randomisation) of 1) spironolactone, 2) systemic steroids, 3) systemic antibiotics, 4) systemic treatment for acne vulgaris (other than oral retinoids, which require a 6-month washout), or 5) systemic anti-inflammatory agents.
- •9. Use within 2 weeks prior to baseline (Randomisation) of 1) topical steroids, 2) topical retinoids, 3) topical acne treatments including over-the-counter preparations, 4) topical anti-inflammatory agents, 5) medicated cleansers/shampoo or 6) topical antibiotics.
- •10. Subjects who have received neuromuscular blocking agents within 14 days prior to study entry (Randomisation).
- •11. Used astringents and toners for less than 2 weeks prior to the start of the study. The subject must have had an established regimen for at least 2 weeks prior to enrolment and must not have anticipated changing their regimen during the conduct of the entire study.
- •12. Used abradants, facials, peels containing glycolic or other acids, masks; washes or soaps containing benzoyl peroxide, salicylic acid, or sulfacetamide sodium; non-mild facial cleansers, moisturizers that contained retinol, salicylic acid or α- or β-hydroxy acids within the previous 2 weeks.
- •13. Concomitant use/planned to use of mega-doses of certain vitamins (such as mega-doses of vitamin D [more than 2000 IU per day], vitamin B6 [more than 2 mg] or vitamin B12 [more than 1 mg per day]), haloperidol, halogens such as iodide and bromide, lithium, hydantoin and phenobarbital.
- •14. Use of tanning booths or tanning lamps within 1 week prior to Baseline and an unwillingness to refrain from use during the study.
- •15. A significant medical history of or are currently immunocompromised or receiving immunomodulators/biologics since last 3 months.
- •16. Have a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
- •17. Subjects with clinically significant unstable medical disorders, life-threatening disease, or current malignancies.
- •18. Subjects who
研究者
相似试验
未知
3 期
A Multicentre, Double-blind, Randomised, Parallel-group, Phase3 Study to Assess Efficacy and Safety of D9421-C 9mg Versus Mesalazine 3g in Patients With Active Crohn's Disease (CD) in JapaCrohn's DiseaseJPRN-jRCT2080221723AstraZeneca
招募中
3 期
A Multicentre, Randomised, Double-blind, Parallel-group, Placebo controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)NL-OMON54266Astra Zeneca3
招募中
1 期
A study to evaluate if benralizumab may be beneficial in the treatment of Hypereosinophilic Syndrome (HES)EUCTR2019-002039-27-ESAstraZeneca AB120
进行中（未招募）
1 期
A study to evaluate if benralizumab may be beneficial in the treatment of Hypereosinophilic Syndrome (HES)Hypereosinophilic Syndrome (HES)MedDRA version: 20.0Level: PTClassification code 10048643Term: Hypereosinophilic syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2019-002039-27-ITASTRAZENECA AB120
进行中（未招募）
1 期
Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasison-cystic fibrosis bronchiectasis (NCFB)MedDRA version: 20.0Level: SOCClassification code 10038738Term: Respiratory, thoracic and mediastinal disordersSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-004068-24-ITASTRAZENECA AB420